-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Thermo Fisher Scientific, a global leader in scientific services, announced on August 9 that it has updated its Applied Biosystems company TaqMan SARS-CoV-2 mutation panel to detect Delta and Lambda strains
.
The research team was first launched in March 2021 and has a customizable and validated real-time PCR detection menu to identify SARS-CoV-2 mutations
The team enables laboratories to track known mutations by selecting from more than 50 testing methods designed to screen for different variants
.
The TaqMan SARS-CoV-2 mutation panel is highly scalable and can run up to hundreds of samples to identify one or more mutations so that the laboratory can expand the monitoring activities according to the testing needs
Manoj Gandhi, Senior Medical Director of Genetic Testing Solutions at Thermo Fisher, said: “SARS-CoV-2 will continue to evolve and may increase the risk of infection in vaccinated and unvaccinated individuals
.
As we learn to interact with this virus When coexisting, monitoring and testing are crucial
The TaqMan SARS-CoV-2 mutation panel is based on the gold standard TaqMan SNP genotyping analysis technology, which can provide results within about an hour, helping to effectively detect and distinguish mutations
.
The panel can be used with real-time PCR instruments and techniques widely used in laboratories around the world